Inactive Instrument

News LENZ Therapeutics, Inc. OTC Markets

Equities

Leerink Partners Starts LENZ Therapeutics With Outperform Rating, $32 Price Target	Apr. 15	MT
William Blair Starts LENZ Therapeutics With Outperform Rating	Apr. 15	MT
LENZ Therapeutics Reports Positive Topline Data From Late-Stage Presbyopia Trials	Apr. 03	MT
LENZ Therapeutics, Inc. Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials	Apr. 03	CI
Lenz Therapeutics' eye disease drugs meet main goal of late-stage study	Apr. 03	RE
LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials	Apr. 03	BU
LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials	Apr. 02	BU
Piper Sandler Initiates LENZ Therapeutics at Overweight With $28 Price Target	Mar. 27	MT
LENZ Therapeutics, Inc.(NasdaqGS:LENZ) added to NASDAQ Composite Index	Mar. 24	CI

No results for this search